drugset / Trial / NCT00845988

Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders

NCT00845988

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary goal of this study is to investigate metabolic changes and maintaining efficacy in stabilized patients with bipolar disorders who have pharmacologically induced weight gain.

Timeline

Start
2008-12
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 10 mg Oral